** Shares of therapy developer Neurogene fall 46.9% to $37.99 aftermarket
** Co says it does not expect to move forward with the development of its gene therapy for Batten disease
** Says the decision was made after the FDA denied co's Regenerative Medicine Advance Therapy (RMAT) application to the FDA for the gene therapy
** A therapy is eligible for RMAT designation if it is used for treating a serious or life-threatening disease or condition and if preliminary clinical evidence shows the therapy has potential to address unmet medical needs
** Co says it is currently evaluating options for the developmental program
** Batten disease is a rare, inherited, and fatal disorder that affects the nervous system
** Up to last close, stock up more than double YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.